Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Amit S. Adhikari"'
Autor:
Amit S. Adhikari, Teresa Sullivan, Rhishikesh Bargaje, Lucy Lu, T Norene O’Sullivan, Yurong Song, Terry Van Dyke
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Glioblastoma (GBM) remains lethal with no effective treatments. Despite the comprehensive identification of commonly perturbed molecular pathways, little is known about the disease’s etiology, particularly in early stages. Several studies indicate
Externí odkaz:
https://doaj.org/article/b2bf47985fe4492d831157f57f0e2890
Autor:
Amit S. Adhikari, Juliete Macauley, Yoshimi Johnson, Mike Connolly, Timothy Coleman, Teri Heiland
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Glioblastoma multiforme (GBM) is an aggressive form of brain cancer with a median survival of 15 months that has remained unchanged despite advances in the standard of care. GBM cells express human cytomegalovirus (HCMV) proteins, providing a unique
Externí odkaz:
https://doaj.org/article/6032ad8fb27449e4b255a8ac775069d1
Autor:
Tomoo Iwakuma, Radhika R. Pochampally, Bernardo Ruiz, Constance Porretta, Byron M. Wood, Neeraj Agarwal, Amit S. Adhikari
Supplementary Materials and Methods from CD117 and Stro-1 Identify Osteosarcoma Tumor-Initiating Cells Associated with Metastasis and Drug Resistance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11e5147bff72d975adc15cb78a75b742
https://doi.org/10.1158/0008-5472.22382051
https://doi.org/10.1158/0008-5472.22382051
Autor:
Tomoo Iwakuma, Radhika R. Pochampally, Bernardo Ruiz, Constance Porretta, Byron M. Wood, Neeraj Agarwal, Amit S. Adhikari
Emerging evidence indicates the presence of tumor-initiating cells (TIC) or cancer stem cells in osteosarcoma. However, no study has shown specific markers to identify osteosarcoma TICs with in vivo tumor formation ability. Additionally, there has be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f9500af59ed0e2f336d19630c64079c
https://doi.org/10.1158/0008-5472.c.6500081.v1
https://doi.org/10.1158/0008-5472.c.6500081.v1
Publikováno v:
PLoS ONE, Vol 12, Iss 6, p e0179168 (2017)
The tumor suppressor p53 plays a crucial role in the development of osteosarcoma. The primary objective of this study is to develop and optimize lipid based nanoparticle formulations that can carry siRNA and effectively silence mutant p53 in 318-1, a
Externí odkaz:
https://doaj.org/article/605c132b09b143a0b3d3d81c243643c0
Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities
Autor:
Alejandro Parrales, Amit S. Adhikari, Swathi V. Iyer, Luis A. Martinez, Tomoo Iwakuma, Priya Begani, Akshay Narkar
Publikováno v:
Oncotarget
Many p53 hotspot mutants not only lose the transcriptional activity, but also show dominant-negative (DN) and oncogenic gain-of-function (GOF) activities. Increasing evidence indicates that knockdown of mutant p53 (mutp53) in cancer cells reduces the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5ba121223bae36073604eca71f1640a
http://europepmc.org/articles/PMC4868694
http://europepmc.org/articles/PMC4868694
Autor:
Tomoo Iwakuma, Swathi V. Iyer, Amit S. Adhikari, Kevon Hekmatdoost, Neeraj Agarwal, Danny R. Welch
Publikováno v:
Oncogene
Murine double minute (MDM2) binding protein (MTBP) has been implicated in cancer progression. Here, we demonstrate one mechanism by which MTBP inhibits cancer metastasis. Overexpression of MTBP in human osteosarcoma cell lines lacking wild-type p53 d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36e9172b05e9f8f412ed43e6e61ea3ff
https://doi.org/10.1038/onc.2012.69
https://doi.org/10.1038/onc.2012.69
Publikováno v:
Cell Death & Differentiation. 18:1208-1219
Murine double minute 2 (MDM2) binding protein (MTBP) has been implicated in tumor cell proliferation, but the underlying mechanisms remain unclear. The results of MTBP expression analysis during cell cycle progression demonstrated that MTBP protein w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e936a93b79425b41b27da4c7e32d341
https://doi.org/10.1038/cdd.2010.189
https://doi.org/10.1038/cdd.2010.189
Autor:
Amit S, Adhikari, Tomoo, Iwakuma
Publikováno v:
福岡醫學雜誌. 100(6):217-228
p53 is an indispensible tumor suppressor and exerts this function by transactivating numerous downstream target genes that play vital roles in controlling cell proliferation, apoptosis, senescence, and DNA repair. Mutations in the p53 gene, which are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::4916d8b6f8033a5e30fddfcce8333095
http://hdl.handle.net/2324/15090
http://hdl.handle.net/2324/15090
Autor:
Amit S. Adhikari, Tomoo Iwakuma, Sruti Chandra, Anup K. Kundu, Swathi V. Iyer, Tarun K. Mandal
Publikováno v:
PLoS ONE
PLoS ONE, Vol 12, Iss 6, p e0179168 (2017)
PLoS ONE, Vol 12, Iss 6, p e0179168 (2017)
Objectives The tumor suppressor p53 plays a crucial role in the development of osteosarcoma. The primary objective of this study is to develop and optimize lipid based nanoparticle formulations that can carry siRNA and effectively silence mutant p53
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fee2b48fc418707aeb376d096b0f70a
https://doi.org/10.1371/journal.pone.0179168
https://doi.org/10.1371/journal.pone.0179168